IFNG and neoplasm: We observed that compared with niraparib or PD-L1 blockade, the combination treatment could significantly increase the levels of IFN-γ and Granzyme B mRNA in tumor tissues, suggesting that the combination of niraparib and PD-L1 blockade therapy could reinforce the cytotoxic effector function of CTL, activate IFN-γ signaling pathway, and further strengthen antitumor immunity.